Seven months after Amgen’s chief medical officer referred to trial results for the company's investigational lung cancer ...

China-made PD-1 inhibitors just can’t get a clean pass through the FDA.  | China-made PD-1 inhibitors continue to struggle at ...

Following a controversy over Covis’ preterm birth drug Makena in the U.S. last year, the European Medicines Agency (EMA) is ...

After Moderna last year suffered a loss in its heated patent fight against Pfizer and BioNTech, the mRNA drugmaker can now ...

Right on the heels of a similar move by Johnson & Johnson, GSK is offloading the rest of its stake in the consumer healthcare ...

A fire broke out Thursday on the roof of a building under construction at Novo Nordisk’s key manufacturing hub in Kalundborg, ...

After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. | A new Senate HELP Committee report says GLP-1 drugs ...

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the ...

The company formerly known as First Wave BioPharma has found itself on dry land with a decidedly non-aquatic new moniker. The ...

Launched amid NF Awareness Month this May, its new campaign “Coping isn’t Care” is aimed at boosting knowledge of ...

AbbVie’s newest psoriasis awareness-raising campaign is taking the skin condition out of the spotlight. | AbbVie’s newest ...

Following a reportedly bullish assessment from Medicare, Eisai has projected a significant sales increase for Leqembi. Takeda ...